FENC Q4 2023 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+551.7% YoY

Gross Profit

$9M93.0% margin

Operating Income

-$2M-18.7% margin

Net Income

-$3M-27.6% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+53.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$857,000

Balance Sheet

Total Assets

$27M

Total Liabilities

$38M

Stockholders' Equity

-$12M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$2M	+551.7%
Gross Profit	$9M	$1M	+541.8%
Operating Income	-$2M	-$6M	+69.5%
Net Income	-$3M	-$8M	+64.6%